CA2929369C - Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds - Google Patents

Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds Download PDF

Info

Publication number
CA2929369C
CA2929369C CA2929369A CA2929369A CA2929369C CA 2929369 C CA2929369 C CA 2929369C CA 2929369 A CA2929369 A CA 2929369A CA 2929369 A CA2929369 A CA 2929369A CA 2929369 C CA2929369 C CA 2929369C
Authority
CA
Canada
Prior art keywords
substituted
alkyl
alkoxy
phosphopantetheine
cyano
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2929369A
Other languages
English (en)
French (fr)
Other versions
CA2929369A1 (en
Inventor
Branko Jenko
Gregor Kosec
Hrvoje Petkovic
Ajda Podgorsek Berke
Jerca PAHOR
Alen CUSAK
Oda Cornelia Maria Sibon
Balaji Srinivasan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vectivbio Coment Ag
Rijksuniversiteit Groningen
Academisch Ziekenhuis Groningen
Original Assignee
Vectivbio Coment Ag
Rijksuniversiteit Groningen
Academisch Ziekenhuis Groningen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vectivbio Coment Ag, Rijksuniversiteit Groningen, Academisch Ziekenhuis Groningen filed Critical Vectivbio Coment Ag
Publication of CA2929369A1 publication Critical patent/CA2929369A1/en
Application granted granted Critical
Publication of CA2929369C publication Critical patent/CA2929369C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2929369A 2013-11-04 2014-10-29 Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds Active CA2929369C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13191457.4 2013-11-04
EP20130191457 EP2868662A1 (en) 2013-11-04 2013-11-04 Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
PCT/EP2014/073258 WO2015063177A1 (en) 2013-11-04 2014-10-29 Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds

Publications (2)

Publication Number Publication Date
CA2929369A1 CA2929369A1 (en) 2015-05-07
CA2929369C true CA2929369C (en) 2023-10-17

Family

ID=49518786

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2929369A Active CA2929369C (en) 2013-11-04 2014-10-29 Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds

Country Status (9)

Country Link
US (2) US9963472B2 (enExample)
EP (2) EP2868662A1 (enExample)
JP (1) JP6568536B2 (enExample)
CN (1) CN105764909B (enExample)
AU (1) AU2014343730B2 (enExample)
CA (1) CA2929369C (enExample)
DK (1) DK3066106T3 (enExample)
ES (1) ES2743921T3 (enExample)
WO (1) WO2015063177A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI24899A (sl) * 2014-12-23 2016-06-30 Acies Bio D.O.O. Fosfopanteteinske spojine,same ali v kombinaciji z inhibitorji HMG-COA reduktaze za zniževanje serumskega holesterola in serumskih trigliceridov
WO2017099822A1 (en) * 2015-12-08 2017-06-15 Retrophin, Inc. Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders
EP3471828A1 (en) 2016-06-16 2019-04-24 Acies Bio d.o.o. Compositions and methods useful for treating diseases characterized by insufficient pantothenate kinase activity
WO2018022529A1 (en) * 2016-07-25 2018-02-01 Retrophin, Inc. Pantetheine derivatives for the treatment of neurologic disorders
CN106365998A (zh) * 2016-08-19 2017-02-01 陕西思尔生物科技有限公司 一种特戊酸碘甲酯的制备方法
CN107422056B (zh) * 2017-08-17 2020-04-24 山东裕欣药业有限公司 一种特戊酸碘甲酯的气相色谱检测方法及其制备方法
WO2020113209A1 (en) * 2018-11-30 2020-06-04 Comet Therapeutics, Inc. Pantetheine derivatives and uses thereof
CN115919822A (zh) * 2022-10-12 2023-04-07 深圳大学 泛硫乙胺在治疗阿尔茨海默病中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE532299A (enExample) * 1953-10-07
WO2003008626A2 (en) 2001-07-20 2003-01-30 Oregon Health And Science University Novel human nucleic acids encoding a pantothenate kinase and methods of use
WO2012017400A1 (en) 2010-08-03 2012-02-09 North-West University Synthesis of acyl-pantetheine derivatives and the use thereof in the synthesis of acyl-coenzyme a derivatives
WO2013163576A1 (en) * 2012-04-27 2013-10-31 Retrophin, Inc. Pantothenate derivatives for the treatment of neurologic disorders

Also Published As

Publication number Publication date
DK3066106T3 (da) 2019-09-16
JP2016536360A (ja) 2016-11-24
CA2929369A1 (en) 2015-05-07
EP3066106B1 (en) 2019-08-14
WO2015063177A1 (en) 2015-05-07
US20160297840A1 (en) 2016-10-13
ES2743921T3 (es) 2020-02-21
JP6568536B2 (ja) 2019-08-28
US9963472B2 (en) 2018-05-08
CN105764909A (zh) 2016-07-13
EP3066106A1 (en) 2016-09-14
CN105764909B (zh) 2019-12-06
EP2868662A1 (en) 2015-05-06
US20180118767A1 (en) 2018-05-03
AU2014343730B2 (en) 2019-08-01

Similar Documents

Publication Publication Date Title
CA2929369C (en) Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
AU2014343730A1 (en) Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (PKAN) and methods for the synthesis of such compounds
AU2017239508B9 (en) Pantothenate derivatives for the treatment of neurologic disorders
US10624908B2 (en) Phosphopantetheine compounds alone or in combination with HMG-CoA reductase inhibitors for lowering serum cholesterol and serum triglicerides
HK1232544A1 (en) Pantothenate derivatives for the treatment of neurologic disorders
HK1207863B (en) Pantothenate derivatives for the treatment of neurologic disorders
HK1232544B (en) Pantothenate derivatives for the treatment of neurologic disorders

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191029

EEER Examination request

Effective date: 20191029

EEER Examination request

Effective date: 20191029

EEER Examination request

Effective date: 20191029

EEER Examination request

Effective date: 20191029

EEER Examination request

Effective date: 20191029

EEER Examination request

Effective date: 20191029

EEER Examination request

Effective date: 20191029

EEER Examination request

Effective date: 20191029

EEER Examination request

Effective date: 20191029

EEER Examination request

Effective date: 20191029

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241025

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241025